The xenograft antigen in complex with GS-1-B$_4$ lectin: crystallization and preliminary X-ray analysis

Wolfram Tempel,[a,b] **Leigh Ann Lipscomb,**[b] **John P. Rose**[b] **and Robert J. Woods**[a,b]*

[a]Complex Carbohydrate Research Center, The University of Georgia, 220 Riverbend Road, Athens, GA 30602, USA, and [b]Department of Biochemistry and Molecular Biology, The University of Georgia, Athens, GA 30602, USA

Correspondence e-mail: rwoods@ccrc.uga.edu

The implantation of animal organs is one approach to overcoming the shortage of human donor organs for medical transplantation. Although readily available, non-primate tissues are subject to hyperacute rejection wherein human anti-Galα(1–3)Gal antibodies react with haptens present on the transplanted cells' surfaces. The understanding of this interaction on a molecular level will further the development of a strategy for the prevention of hyperacute rejection in xenotransplantation. The Galα(1–3)Gal hapten ('xenograft antigen') has been cocrystallized with the Gal-specific B$_4$ isolectin of *Griffonia simplicifolia* lectin-1. Crystals were analyzed by cryocrystallography and were found to diffract to moderately high resolution on a rotating-anode X-ray source. They belong to the $P2_12_12$ space group, with unit-cell parameters $a = 111.0$, $b = 51.3$, $c = 76.9$ Å, and contain two molecules per asymmetric unit.

1. Introduction

In the process of hyperacute rejection (Platt & Bach, 1991), Galα(1–3)Galβ(1–4)GlcNAc-R, known as the xenograft antigen, triggers the rejection of non-primate tissues from human transplant recipients (Good *et al.*, 1992; Sandrin *et al.*, 1993; Galili, 1993). The ubiquitous presence of anti-Galα(1–3)Gal antibodies in humans, Old World monkeys and apes is paralleled by the absence of Galα(1–3)Gal on the cell surfaces of those species (Galili *et al.*, 1987). Evolutionary pressure may have led to the suppression of α1,3-galactosyltransferase and thus the absence of Galα(1–3)Gal epitopes in those cases (Galili, 1999).

G. simplicifolia lectin-1 (GS-1) is a carbohydrate-binding protein present in the seeds of the African leguminous shrub. As isolated, GS-1 is a mixture of five tetrameric isolectins that vary in their content of *A* and *B* subunits (Murphy & Goldstein, 1977). Similar to other legume lectins, GS-1 loses its carbohydrate-binding activity upon removal of metal ions (Hayes & Goldstein, 1974) and it has been postulated (Loris *et al.*, 1998) that the simultaneous presence of both Ca^{2+} and a transition-metal ion such as Mn^{2+} is required for carbohydrate-binding activity of these lectins. Indeed, Mn^{2+} and Ca^{2+} are both observed in the reported structure of a complex of *G. simplicifolia* lectin-4 (Delbaere *et al.*, 1993). In contrast, the addition of Ca^{2+} alone can restore GS-1 activity from samples where Mn^{2+} and Zn^{2+} have been removed beyond the limit of detection (Hayes & Goldstein, 1974).

Labelled derivatives of GS-1 isolectin B$_4$ (GS-1-B$_4$) are distributed commercially as a marker for non-primate mammalian tissues (Laitinen *et al.*, 1987; Laitinen, 1987; Christie & Thomson, 1989). Competitive binding studies have shown affinity of GS-1-B$_4$ for the Galα(1–3)Gal epitope (Wood *et al.*, 1979). It has also become a useful tool in structural studies of xenograft-antigen recognition. In fact, inhibitors of anti-Galα(1–3)Gal antibodies also block carbohydrate binding to GS-1-B$_4$ (Kooyman *et al.*, 1996; Vaughan *et al.*, 1996; Sandrin *et al.*, 1997). In an effort to improve understanding of xenograft-antigen recognition at a structural level, we undertook the crystal structure analysis of the GS-1-B$_4$–Galα(1–3)Gal complex by X-ray diffraction. The structure will serve as the basis for the design of effective inhibitors of Galα(1–3)Gal binding to both GS-1-B$_4$ and, owing to the cross-reactivity established in several studies, to anti-Galα(1–3)Gal antibodies. It is therefore anticipated that the structural information resulting from this effort will contribute to the development of structure-based approaches to the prevention of xenograft rejection (McKenzie *et al.*, 1996).

2. Materials and methods

Lectin-1 isolectin B$_4$ from *G. simplicifolia*, GS-1-B$_4$, was purchased from Vector Laboratories (catalog No. L1104) and used without further purification. Galα(1–3)Gal β-methyl glycoside was purchased from Calbiochem-Novabiochem Corporation (catalog No. 345523) and used without further purification. The protein was reconstituted to the desired concentration in a solution containing 10 mM

crystallization papers

Table 1
Data-processing statistics.

Resolution range (Å)	30.00–2.65	2.77–2.65
No. of unique observed reflections	12864	1541
Completeness (%)	97.4	95.9
$\langle I \rangle / \langle \sigma \rangle$	27.8	6.7
Redundancy for unique reflections		
>3 observations (%)	94.7	91.27
>6 observations (%)	80.5	77.2
R_{merge}† (%)	6.9	28.0

† $R_{merge} = \sum |I - \langle I \rangle| / \sum I$.

HEPES buffer pH 8.5, 150 mM NaCl, 0.1 mM CaCl$_2$, 0.08% NaN$_3$ and 1.1 mM Galα(1–3)Galβ-methyl glycoside. This solution was passed through a 0.2 μm filter prior to crystallization experiments.

Crystallization experiments were conducted at 293 K using hanging-drop vapor diffusion. Linbro plates (Hampton Research, HR3-110) and siliconized cover slides (Hampton Research, HR3-241) were used. The volume of reservoir precipitant solution was 500 μl. Initial screening for crystallization conditions was carried out with the Hampton Crystal Screen kit (Hampton Research, HR2-110) by mixing 2 μl of protein solution (protein concentration 5 mg ml^{-1}) with an equal volume of precipitant solution. For the preparation of diffraction-quality crystals, 1.5 μl of protein solution (protein concentration 10 mg ml^{-1}) was mixed first with 0.3 μl [0.02%(w/v)] of detergent NP-40 (Calbiochem-Nova-biochem, 492015) and then with 1.5 μl of precipitant solution [11%(w/v) PEG 4000, 8%(v/v) MPD, 6%(v/v) DMSO, 0.1 M HEPES buffer pH 7.5].

Crystals were mounted in loops (Teng, 1990; Hampton Research, HR4-955) and placed in a stream of cold (93 K) nitrogen gas after brief (few seconds) incubation in a 1:3(v/v) mixture of neat MPD and precipitant solution. Data were recorded using 5 kW Cu $K\alpha$ radiation generated by a Rigaku RU-200 rotating anode and focused with MSC Blue confocal optics. A total of 198 1° oscillation images (Fig. 1), each exposed for 15 min, were collected on a Rigaku R-AXIS IV image-plate detector using a crystal-to-detector distance of 180 mm. External control of the goniostat, generator and detector was provided by a PC running *CrystalClear* (Molecular Structure Corporation). Data were indexed, integrated and scaled using the *HKL* suite (Otwinowski & Minor, 1997).

For molecular replacement, the *CNS* software suite (Brunger *et al.*, 1998) was used employing the peptide chain of PDB file 1gsl (Delbaere *et al.*, 1993) as a search model.

3. Results and discussion

It is of interest to note that *G. simplicifolia* lectin-1 has eluded previous attempts at crystallographic analysis (Goldstein, 2000). This is consistent with our own failure to produce well diffracting crystals of the native protein in the absence of carbohydrate ligand.

Galα(1–3)Galβ-methyl glycoside (Fig. 2) was chosen as the carbohydrate ligand for the purpose of this study. It conserves the terminus of the α-Gal epitope Galα(1–3)Galβ(1–4)GlcNAc-R which is found on non-primate mammalian cells. In the presence of carbohydrate ligand, sparse-matrix screening (Jancarik & Kim, 1991) produced small crystals with a precipitant solution consisting of 20%(w/v) PEG 4000, 10%(v/v) 2-propanol, 0.1 M HEPES buffer pH 7.5. We noticed that crystal stability was compromised during crystal handling owing to evaporation of 2-propanol. This problem was overcome through substitution of 10%(v/v) MPD for 2-propanol. Modification of precipitant concentration had the most noticeable effect on the final crystal size. For the preparation of diffraction-quality crystals the concentration of lectin in the protein–ligand solution was doubled to 10 mg ml^{-1}, thereby reducing the optimum concentration of PEG 4000 in the precipitant solution. The addition of DMSO to the well solution and of NP-40 to the crystallization drop improved the final crystal size and inhibited the formation of precipitate. The beneficial effect of addition of DMSO to the precipitant solution is likely to be the result of precipitant dilution. Crystals with excellent morphology and measuring approximately 0.05 mm in their largest dimension were observed after 2–3 d. These crystals grew to a size of approximately 0.15 mm within two weeks (see Fig. 3).

Crystals were initially mounted without additional cryoprotecting treatment. Although ice rings were not visible on the oscillation images, a high crystal mosaicity was apparent. We therefore briefly

Figure 2
For the purpose of this study, the xenograft antigen was presented as the β-methyl glycoside.

Figure 1
Typical 1° oscillation image obtained during data collection. In the zoomed image (right), a reflection at 2.65 Å and I/σ of 2.4 is marked by the cross hair. I/σ for this reflection is also illustrated by the intensity profiles at the lower and right-hand side margins of the images.

Figure 3
Crystal of GS-B$_4$ grown in the presence of Galα(1–3)Galβ-OMe.

immersed crystals into a 1:3(v/v) mixture of neat MPD and precipitant solution prior to mounting of the crystal in the X-ray beam and found the mosaicity acceptable.


Figure 4
Representation of crystal packing: the C^α trace of PDB file 1gsl is placed in the unit cell according to the structure solution by molecular replacement. For each of the four asymmetric units shown, subunit 1 is drawn in yellow, while subunit 2 can be seen in blue. For clarity, the cell origin was shifted along y by one half of the unit-cell edge. The contents of the two asymmetric units in the center of the unit cell constitute the biologically active tetramer. This image was generated using the program *RasMol* (Bernstein, 2001).

The data indexed in a primitive orthorhombic lattice and gave refined unit-cell parameters $a = 111.0$, $b = 51.3$, $c = 76.9$ Å. Refinement of mosaicity gave an average value of $1.0°$ over all images. Data-processing statistics are listed in Table 1. Examination of the three-dimensional data set gave systematic absences of $h = 2n + 1$ in $h00$ and $k = 2n + 1$ in $0k0$, indicating that the space group is $P2_12_12$ (Table 1).

Structure solution by molecular replacement was attempted using several lectin structures as search models. The GS-4 structure (PDB code 1gsl; Delbaere *et al.*, 1993) produced the best results. Although the sequencing of GS-1-B$_4$ is in progress, a *BLAST* (Altschul *et al.*, 1990) alignment of the N-terminal GS-1-B$_4$ sequence (Lamb & Goldstein, 1984) showed a 44% identity with that of GS-4. The initial cross-rotation search (DeLano & Brünger, 1995) gave a solution

with a rotation function value of 0.0657 at $\varepsilon = 0.25$ at $\theta_1 = 334$, $\theta_2 = 78$, $\theta_3 = 278°$. Using this solution, the translation search (Navaza & Vernoslova, 1995) followed by rigid-body refinement placed the single polypeptide chain at $\theta_1 = 332$, $\theta_2 = 78$, $\theta_3 = 278°$, $x_{trans} = 42.2$, $y_{trans} = 7.6$, $z_{trans} = 13.8$ Å with an R factor of 54.6% and a packing coefficient of 0.36 using 8–4 Å resolution data. The second molecule in the asymmetric unit was placed at $\theta_1 = 332$, $\theta_2 = 79$, $\theta_3 = 203°$, $x_{trans} = -11.0$, $y_{trans} = 15.3$, $z_{trans} = 24.7$ Å by fixing the coordinates of the first molecule and performing translation searches on the remaining cross-rotation function solutions. After placing the second molecule in the asymmetric unit, the crystallographic residual improved to 47.3%, with a packing coefficient of 0.70. The crystal packing is represented in Fig. 4. Based on this structure solution and assuming a molecular weight of 30.4 kDa for each subunit, the Matthews coefficient and solvent content are calculated to be 1.8 Å Da^{-1} and 32%, respectively. These values fall at the low end of the range determined for the original set of protein crystals (Matthews, 1968).

Complete structural refinement is awaiting the outcome of amino-acid sequence determination of GS-1-B$_4$. However, initial electron-density maps calculated from the molecular-replacement phases (*CNS*) showed density for the carbohydrate ligand in the lectin's putative binding site (see Fig. 5). The fully refined GS-1-B$_4$–Galα(1–3)Galβ-methyl glycoside structure will reveal details of xenograft-antigen recognition by a protein that exhibits a high degree of cross-reactivity with the antibodies that cause the hyperacute rejection of xenografts in primates.

References

Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. (1990). *J. Mol. Biol.* **215**, 403–410.
Bernstein, H. J. (2001). *RasMol* Version 2.7.1.1, http://www.bernstein-plus-sons.com/software/rasmol/.
Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T. & Warren, G. L. (1998). *Acta Cryst.* D**54**, 905–921.
Christie, K. N. & Thomson, C. (1989). *J. Histochem. Cytochem.* **37**, 1303–1304.

Figure 5
The images depict a region of the asymmetric unit where specific binding of a carbohydrate ligand by the lectin is expected to occur by homology with the GS-4 complex in 1gsl. In (*a*) a $2F_o - F_c$ difference map is shown at 1.3σ (blue); in (*b*) a $F_o - F_c$ map at 2.7σ can be seen in red for the same region. Ligand coordinates were not included for the map calculation but are shown here for clarity as a ball-and-stick model. The numbering of peptide side chains conforms to that used in 1gsl. The images were generated using the program *O* (Jones *et al.*, 1991).

crystallization papers

DeLano, W. L. & Brünger, A. T. (1995). *Acta Cryst.* D**51**, 740–748.

Delbaere, L. T., Vandonselaar, M., Prasad, L., Quail, J. W., Wilson, K. S. & Dauter, Z. (1993). *J. Mol. Biol.* **230**, 950–965.

Galili, U. (1993). *Immunol. Today*, **14**, 480–482.

Galili, U. (1999). *Subcellular Biochemistry*, Vol. 32, *α-Gal and Anti-Gal*, edited by U. Galili & J. L. Avila, pp. 1–23. New York: Kluwer Academic/Plenum Press.

Galili, U., Clark, M. R., Shohet, S. B., Buehler, J. & Macher, B. A. (1987). *Proc. Natl Acad. Sci. USA*, **84**, 1369–1373.

Goldstein, I. J. (2000). Personal communication.

Good, A. H., Cooper, D. K. C., Malcolm, A. J., Ippolito, R. M., Koren, E. Neethling, F. A., Ye, Y., Zuhdi, N & Lamontagne, L. R. (1992). *Transplant. Proc.* **24**, 559–562.

Hayes, C. E. & Goldstein, I. J. (1974). *J. Biol. Chem.* **249**, 1904–1914.

Jancarik, J. & Kim, S.-H. (1991). *J. Appl. Cryst.* **24**, 409–411.

Jones, T. A., Zou, J. Y., Cowan, S. W. & Kjeldgaard, M. (1991). *Acta Cryst.* A**47**, 110–119.

Kooyman, D. L., McClellan, S. B., Parker, W., Avissar, P. L., Velardo, M. A., Platt, J. L. & Logan, J. S. (1996). *Transplantation*, **61**, 851–855.

Laitinen, L. (1987). *Histochem. J.* **19**, 225–234.

Laitinen, L., Virtanen, I. & Saxen, L. (1987). *J. Histochem. Cytochem.* **35**, 55–65.

Lamb, J. E. & Goldstein, I. J. (1984). *Arch. Biochem. Biophys.* **229**, 15–26.

Loris, R., Hamelryck, T., Bouckaert, J. & Wyns, L. (1998). *Biochim. Biophys. Acta*, **1383**, 9–36.

McKenzie, I. F. C., Osman, N., Cohney, S., Vaughan, H. A., Patton, K., Mouhtouris, E., Atkin, J. D., Elliott, E., Fodor, W. L., Squinto, S. P., Burton, D., Gallop, M. A., Oldenburg, K. R. & Sandrin, M. S. (1996). *Transplantation Proc.* **28**, 537.

Matthews, B. W. (1968). *J. Mol. Biol.* **33**, 491–497.

Murphy, L. A. & Goldstein, I. J. (1977). *J. Biol. Chem.* **252**, 4739–4742.

Navaza, J. & Vernoslova, E. (1995). *Acta Cryst.* A**51**, 445–449.

Otwinowski, Z. & Minor, W. (1997). *Methods Enzymol.* **276**, 307–326.

Platt, J. L. & Bach, F. H. (1991). *Curr. Opin. Immunol.* **3**, 735–739.

Sandrin, M. S., Vaughan, H. A., Dabkowski, P. L. & McKenzie, I. F. C. (1993). *Proc. Natl Acad. Sci. USA*, **90**, 11391–11395.

Sandrin, M. S., Vaughan, H. A., Xing, P. X. & McKenzie, I. F. C. (1997). *Glycoconj. J.* **14**, 97–105.

Teng, T. Y. (1990). *J. Appl. Cryst.* **23**, 387–391.

Vaughan, H. A., Oldenburg, K. R., Gallop, M. A., Atkin, J. D., McKenzie, I. F. C. & Sandrin, M. S. (1996). *Xenotransplantation*, **3**, 18–23.

Wood, C., Kabat, E. A., Murphy, L. A. & Goldstein, I. J. (1979). *Arch. Biochem. Biophys.* **198**, 1–11.